C

Colorado Retina Associates | Lakewood, CO

Research site

(Unclaimed)

Location

255 South Routt Street Suite 200, Lakewood, Colorado, United States of America

Site insights

Top conditions

Top treatments

ABP 938

EYE103

Zimura

AU-011

Aflibercept

Pegcetacoplan

Eylea®

Parent organization

This site is a part of Colorado Retina Associates

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 8 total trials

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling

Neovascular (Wet) Age-Related Macular Degeneration

Biological: 4D-150 IVT

Biological: Aflibercept IVT

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling

Indeterminate Lesions

Ocular Melanoma

Device: Suprachoroidal Microinjector

Drug: Sham Treatment

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Genetic: RGX-314 Dose 2

Biological: Aflibercept (EYLEA®)